Business And Finance In Brief
Merck and Schering-Plough - it's official: The ribbon is wrapped around the merger between the two companies. Shareholders of both approved the deal Aug. 7
You may also be interested in...
Embeda to launch in September backed by 610 sales reps, Chief Commercial Officer Andrzejewski says.
The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins